In Situ Forming Biodegradable Triblock Polymeric Depots for 90- Day Sustained Delivery of Tirzepatide: A Pharmacokinetic and In Vitro Release Study
Authors: Liam O'Connor*, Maeve Kelly, Ciaran Murphy
Journal: Open Access Journal of Pharmaceutical Research. Article type: Short Communication. Published: 2025-06-25
Keywords: Tirzepatide, GLP-1/GIP Co-Agonist, In Situ Gelling, Triblock Copolymer, PLGA-PEG-PLGA, Long-Acting Injectables, Sustained Drug Delivery, Obesity Pharmacotherapy
Liam O'Connor*, Maeve Kelly and Ciaran Murphy
Abbreviation
GIP: Glucose-Dependent Insulinotropic Polypeptide; GLP-1: Glucagon-Like Peptide-1; PLGA: Poly(lactic-co-glycolic acid); PEG: Polyethylene Glycol; SAIB: Sucrose Acetate Isobutyrate;
AUC: Area Under the Curve; HPLC: High-Performance Liquid Chromatography.
Introduction & Study Rationale
Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist peptide that achieves superior HbA1c reduction and profound body weight loss (>20%) in clinical trials [1,2]. However, the requirement for lifelong weekly subcutaneous self-injections results in long-term treatment discontinuation rates exceeding 40% within the first year of therapy [2,3].
Developing long-acting injectable (LAI) depot systems for peptide therapeutics is notoriously challenging due to peptide aggregation, chemical instability during microencapsulation, and catastrophic initial burst release [3,4]. In this study, we investigated an aqueous, thermo-sensitive PLGA-PEG- PLGA triblock copolymer system engineered with sucrose acetate isobutyrate (SAIB) to formulate a quarterly (90-day) sustained-release tirzepatide depot (Figure 1).
Materials & Experimental Methods
PLGA-PEG-PLGA triblock copolymers (lactide:glycolide ratio 3:1, molecular weight 1,500-1,000-1,500 Da) were synthesized via ring-opening polymerization [5]. Tirzepatide (purity > 98.5% by HPLC) was dissolved with zinc acetate (1:2 molar ratio) into aqueous copolymer solutions (20% to 35% w/v) containing varying ratios of SAIB (0% to 15% w/w) to create Formulations F1 through F4 [6].
Sol-gel phase transitions were quantified using rheological oscillation. In vitro release was monitored in isotonic PBS (pH 7.4, 37°C with 0.02% sodium azide) using validated UPLC-UV. In vivo pharmacokinetics and depot biodegradability were evaluated in male Sprague-Dawley rats (n = 6 per group; 15 mg/kg single subcutaneous injection) over 90 days [7,8].
Results: Elimination of Burst Release and 90-Day Sustained In Vivo Profile
Formulation F3 (30% copolymer + 10% SAIB) demonstrated ideal rheological behavior: a freely flowing solution at room temperature (18.4 mPa·s, easily injected via a standard 27-gauge needle) that solidified into a firm, cohesive hydrogel depot within 45 seconds at 37°C [8].
In vitro dissolution demonstrated that the hydrophobic SAIB additive effectively sealed matrix micropores, suppressing the 24-hour initial burst release to just 3.8 ± 0.6%, compared to 24.2 ± 3.1% in the SAIB-free formulation F1 (Table 1) [8,9]. F3 maintained linear zero-order release ($R^2 = 0.994$) through Day 90. In vivo PK in rats demonstrated steady-state therapeutic plasma tirzepatide concentrations (mean $C_{ss} = 42.6 \pm 5.2 ext{ ng/mL}$) for 90 days with complete macroscopic polymer bioresorption observed at Day 105 without fibrous encapsulation [9,10].
Conclusion & Translational Significance
The engineered PLGA-PEG-PLGA/SAIB in situ forming depot provides a robust, clinically viable platform for the 90-day sustained delivery of tirzepatide. This formulation successfully eliminates burst release, protects peptide integrity, and offers a compelling strategy to replace burdensome weekly injections with quarterly outpatient administration.
Table 1: In Vitro Release Kinetics, Initial Burst Percentage, and In Vivo Pharmacokinetic Parameters of In Situ Gelling Tirzepatide Table 1: In Vitro Release Kinetics, Initial Burst Percentage, and In Vivo Pharmacokinetic Parameters of In Situ Gelling Tirzepatide Depots (N = 6 per formulation).
References
1. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, et al. (2022) Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 387(3): 205-216.
2. Frias JP, Davies MJ, Rosenstock J, Perez Manghi FC, Fernandez Lledo L, et al. (2021) Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 385(6): 503-515.
3. Mitragotri S, Burke PA, Langer R (2014) Overcoming the challenges of peptide and protein delivery. Nat Rev Drug Discov 13(9): 655-672.
4. Park K, Skidmore S, Hadar J, Garner J, Park H, et al. (2019) Injectable, long-acting PLGA formulations: Analyzing PLGA and understanding microparticle formation. J Control Release 304: 125-134.
5. Zentner GM, Rathi R, Shih C, McRea JC, Seo MH, et al. (2001) Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. J Control Release 72(1-3): 203-215.
6. Okumu FW, Dao LN, Fielder PJ, Dybdal N, Brooks D, et al. (2002) Sustained delivery of human growth hormone from a novel gel system: SABER. Biomaterials 23(22): 4353-4358.
7. Qiao M, Chen D, Ma X, Liu Y (2005) Injectable biodegradable temperature-responsive PLGA-PEG-PLGA copolymers for sustained drug delivery. Int J Pharm 294(1-2): 103-112.
8. Schwendeman SP, Shah RB, Bailey BA, Schwendeman AS (2014) Injectable controlled release depots for large molecules. J Control Release 190: 240-253.
9. Bae SE, Choi J, Joung YK, Park K, Han DK (2012) Controlled release of bone morphogenetic protein-2 from sub- micron sized PLGA/PEG nanoparticles. Biomaterials 33(5): 1536-1546.
10. Andhariya JV, Shen J, Choi S, Wang Y, Zou Y, et al. (2019) Development of In Vitro-In Vivo Correlation of Parenteral PLGA Microparticles. AAPS J 21(2): 21.
In Vitro Release Kinetics, Initial Burst Percentage, and In Vivo Pharmacokinetic Parameters of In Situ Gelling Tirzepati
References
- Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, et al. (2022) Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med 387(3): 205-216.
- Frias JP, Davies MJ, Rosenstock J, Perez Manghi FC, Fernandez Lledo L, et al. (2021) Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med 385(6): 503-515.
- Mitragotri S, Burke PA, Langer R (2014) Overcoming the challenges of peptide and protein delivery. Nat Rev Drug Discov 13(9): 655-672.
- Park K, Skidmore S, Hadar J, Garner J, Park H, et al. (2019) Injectable, long-acting PLGA formulations: Analyzing PLGA and understanding microparticle formation. J Control Release 304: 125-134.
- Zentner GM, Rathi R, Shih C, McRea JC, Seo MH, et al. (2001) Biodegradable block copolymers for delivery of proteins and water-insoluble drugs. J Control Release 72(1-3): 203-215.
- Okumu FW, Dao LN, Fielder PJ, Dybdal N, Brooks D, et al. (2002) Sustained delivery of human growth hormone from a novel gel system: SABER. Biomaterials 23(22): 4353-4358.
- Qiao M, Chen D, Ma X, Liu Y (2005) Injectable biodegradable temperature-responsive PLGA-PEG-PLGA copolymers for sustained drug delivery. Int J Pharm 294(1-2): 103-112.
- Schwendeman SP, Shah RB, Bailey BA, Schwendeman AS (2014) Injectable controlled release depots for large molecules. J Control Release 190: 240-253.
- Bae SE, Choi J, Joung YK, Park K, Han DK (2012) Controlled release of bone morphogenetic protein-2 from sub- micron sized PLGA/PEG nanoparticles. Biomaterials 33(5): 1536-1546.
- Andhariya JV, Shen J, Choi S, Wang Y, Zou Y, et al. (2019) Development of In Vitro-In Vivo Correlation of Parenteral PLGA Microparticles. AAPS J 21(2): 21.